STOCKHOLDERS EQUITY (Tables)

12 Months Ended

Dec. 31, 2022

STOCKHOLDERS' EQUITY [Abstract]

Schedule of Assumptions

The grant date fair values of stock options awarded during the years ended December 31, 2022 and 2021 were determined using the Black-Scholes option pricing model with the following assumptions:

	Years Ended
	December 31, 2022			December 31, 2021
Expected term	5.5-6.3 years			5.5-6.3 years
Volatility		68	%		68-70	%
Dividend yield		0.0			0.0
Risk-free interest rate		1.72-1.73	%		0.80-1.27	%

Schedule of Option Activity

The following table summarizes information about stock options outstanding as of December 31, 2022 and 2021:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2020		6,922,931		$	4.40
Forfeited		(529,202	)	$	2.89
Expired		(426,557	)	$	4.91
Granted		1,895,550		$	2.14
Exercised		-		$	-
Options outstanding, vested and expected to vest at December 31, 2021		7,862,722		$	3.93
Forfeited		(31,540	)	$	2.37
Expired		(700,324	)	$	6.86
Granted		1,194,032		$	1.67
Exercised		(68,679	)	$	2.55
Options outstanding, vested and expected to vest at December 31, 2022		8,256,211		$	3.37
Options exercisable		6,213,959		$	3.80

Summary of Outstanding and Exercisable Options by Price Range

The following table summarizes additional information regarding outstanding and exercisable options under the stock option plans at December 31, 2022:

	Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value
$1.10 - $1.67		1,523,824		9.1	$	1.61	$	3,452,237		406,160		9.0	$	1.52	$	959,663
$1.73 - $2.60		1,623,353		8.0	$	2.35		2,491,181		943,200		8.0	$	2.36		1,430,931
$2.62 - $3.93		4,083,311		5.0	$	3.46		1,696,824		3,852,447		4.8	$	3.49		1,495,461
$3.98 - $5.97		470,428		4.7	$	5.03		-		456,857		4.6	$	5.06		-
$6.02 - $9.03		307,795		1.5	$	8.05		-		307,795		1.5	$	8.05		-
$9.37 - $10.80		247,500		1.9	$	10.28		-		247,500		1.9	$	10.28		-
		8,256,211		6.1	$	3.37	$	7,640,242		6,213,959		5.3	$	3.80	$	3,886,055

Schedule of Unvested RSU Activity

A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2020		326,000		$	2.81
Granted		4,384,744		$	1.30
Vested		(92,750	)	$	2.82
Forfeited		(132,861	)	$	2.51
Balance at December 31, 2021		4,485,133		$	1.34
Granted		1,174,266		$	1.74
Vested		(2,727,412	)	$	1.25
Forfeited		(65,000	)	$	1.40
Balance at December 31, 2022		2,866,987		$	1.59

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the years ended December 31, 2022 and 2021 was as follows:

	2022		2021
Research and development	$	19,476	$	153,924
Plasma center operating expenses		81,668		60,257
Selling, general and administrative		4,716,219		2,958,008
Cost of product revenue		397,168		316,064
Total stock-based compensation expense	$	5,214,531	$	3,488,253